1
|
Cuesta Esteve I, Fernández Fernández P, López Palacios S, Menor Rodríguez MJ, Parra Vino H, Reyero Ortega B, Nieto Nevot ML, Drago Manchón G, López-Belmonte JL. Health care professionals' preference for a fully liquid, ready-to-use hexavalent vaccine in Spain. Prev Med Rep 2021; 22:101376. [PMID: 33996389 PMCID: PMC8105659 DOI: 10.1016/j.pmedr.2021.101376] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2020] [Revised: 02/09/2021] [Accepted: 03/21/2021] [Indexed: 11/30/2022] Open
Abstract
Biosafety devices are needed to safely administer vaccines. Use of “ready-to-use” vaccines can avoid biological accidents. Majority of nurses showed concerns about using lyophilized vaccines.
Vaccination is an effective health intervention for the prevention of infectious diseases. This study aims to evaluate the response provided by nurses toward the use of ready-to-use (RTU) formulations of hexavalent vaccines and measures to prevent errors during the vaccination process. This observational, descriptive, cross-sectional study took place from March to May 2018. It included 201 interviews with nurses from health centers in Madrid (70), Murcia (59), and Andalusia (72), who had administered RTU vaccines in the last 12 months. Approximately 91.6% of nurses provided a positive feedback for the use of RTU vaccines. The most significant concerns experienced by nurses were during the preparation and administration of vaccines; 84.1% versus 18.9% of nurses felt that the risk of making mistakes was lower while using RTU vaccines compared with non-reconstituted (lyophilized) vaccines, and 74.1% versus 22.4% of nurses felt ease at preparing RTU vaccines compared with lyophilized vaccines. A total of 66.7% of nurses believed that there were risks associated with the preparation of lyophilized vaccines (administration risk [42.8%] and risk of needle injury [42.3%]). Risk percentages reduced to 4% and 9.5%, respectively, with the use of the RTU vaccines. Therefore, nurses adopted an average of seven steps to reduce the risk of errors. The average time saved during the administration of the vaccines was 1.1 min. In summary, nurses highlighted the need for administering vaccines using RTU formulations for ensuring the safety of the recipients, preventing errors, and saving time during the vaccination process.
Collapse
Key Words
- DTPa HBV-IPV, diphtheria-tetanus-acellular pertussis-hepatitis B recombinant (adsorbed)-inactivated poliomyelitis-adsorbed conjugated Haemophilus influenzae type b vaccine
- DTaP, diphtheria, tetanus, and acellular pertussis (whooping cough)
- HB, hepatitis B
- HCP, healthcare professionals
- HPV, human papillomavirus
- Hib, Haemophilus influenzae type b
- ICC/ESOMAR, International Chamber of Commerce/European Society for Opinion and Market Research
- IPV, inactivated polio vaccine
- Lyophilized vaccines
- MM, measles, mumps
- MMR, measles, mumps, rubella
- Medication errors
- MenACWY, meningococcal conjugate vaccine
- MenC, meningococcal C vaccine
- PCV, pneumococcal conjugate vaccine
- Pediatric vaccination
- Primary healthcare
- RTU, ready-to-use
- Ready-to-use vaccines
- Td, tetanus, diphtheria
- Vaccination
- WHO, World Health Organization
Collapse
Affiliation(s)
- Inmaculada Cuesta Esteve
- Vaccine Expert Group of the General Council of Nurses, Calle Fuente del Rey, s/n, 28023 Madrid, Spain
| | | | - Sonia López Palacios
- Vaccine Expert Group of the General Council of Nurses, Calle Fuente del Rey, s/n, 28023 Madrid, Spain
| | | | - Hosanna Parra Vino
- Group of the General Council of Nurses, Calle Fuente del Rey, s/n, 28023 Madrid, Spain
| | - Begoña Reyero Ortega
- Group of the General Council of Nurses, Calle Fuente del Rey, s/n, 28023 Madrid, Spain
| | | | - Georgina Drago Manchón
- Sanofi Pasteur, Calle de Josep Pla, 2, 08019 Barcelona, Spain
- Corresponding author at: Sanofi Pasteur, Calle de Josep Pla, 2, 08019 Barcelona, Spain.
| | | |
Collapse
|
2
|
Abstract
Background Pneumonia is the most common cause of death in children worldwide, accounting for 15% of all deaths of children under 5 years of age. This review summarises the evidence for the empirical antibiotic treatment of community-acquired pneumonia in neonates and children and puts emphasis on publications since the release of the previous WHO Evidence Summary report published in 2014. Methods A systematic search for systematic reviews and meta-analyses of antibiotic therapy for community-acquired pneumonia was conducted between 1 January 2013 and 10 November 2016. Results The optimal dosing recommendation for amoxicillin remains unclear with limited pharmacological and clinical evidence. There is limited evidence from surveillance to indicate whether amoxicillin or broader spectrum antibiotics (e.g. third-generation cephalosporins) are being used most commonly for paediatric CAP in different WHO regions. Data are lacking on clinical efficacy in the context of pneumococcal, staphylococcal and mycoplasma disease and the relative contributions of varying first-line and step-down options to the selection of such resistance. Conclusion Further pragmatic trials are required to optimise management of hospitalised children with severe and very severe pneumonia.
Collapse
Key Words
- AAD, antibiotic-associated diarrhoea
- BNFc, British National Formulary for Children
- BTS, British Thoracic Society
- CAP, community-acquired pneumonia
- CPS, Canadian Paediatric Society
- EARS-Net, European Antimicrobial Resistance Surveillance Network
- ESPID, European Society for Paediatric Infectious Diseases
- GRADE, Grading of Recommendations Assessment, Development and Evaluation
- IDSA, Infectious Diseases Society of America
- IMCI, integrated management of childhood illness
- PCV, pneumococcal conjugate vaccine
- PIDS, Pediatric Infectious Diseases Society
- Pneumonia
- RCPCH, Royal College of Paediatrics and Child Health
- WHO, World Health Organization
- antimicrobial resistance
- bacterial
- community-acquired pneumonia
Collapse
Affiliation(s)
- Shrey Mathur
- Paediatric Infectious Disease Research Group, Institute for Infection and Immunity, St George’s University of London, London, UK,Corresponding author.
| | - Aline Fuchs
- Paediatric Pharmacology and Pharmacometrics, University Children’s Hospital Basel, Basel, Switzerland
| | - Julia Bielicki
- Paediatric Infectious Disease Research Group, Institute for Infection and Immunity, St George’s University of London, London, UK,Paediatric Pharmacology and Pharmacometrics, University Children’s Hospital Basel, Basel, Switzerland
| | - Johannes Van Den Anker
- Paediatric Pharmacology and Pharmacometrics, University Children’s Hospital Basel, Basel, Switzerland,Division of Clinical Pharmacology, Children’s National Health System, Washington, DC, USA
| | - Mike Sharland
- Paediatric Infectious Disease Research Group, Institute for Infection and Immunity, St George’s University of London, London, UK
| |
Collapse
|
3
|
Dicko A, Dicko Y, Barry A, Sidibe Y, Mahamar A, Santara G, Dolo A, Diallo A, Doumbo O, Shafi F, François N, Yarzabal JP, Strezova A, Borys D, Schuerman L. Safety, reactogenicity and immunogenicity of 2-dose catch-up vaccination with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Malian children in the second year of life: Results from an open study. Hum Vaccin Immunother 2016; 11:2207-14. [PMID: 26020101 PMCID: PMC4635909 DOI: 10.1080/21645515.2015.1016679] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Pneumonia is still the leading cause of death among African children with pneumococcal serotypes 1 and 5 being dominant in the below 5 y of age group. The present study assessed the safety, reactogenicity and immunogenicity of a 2-dose catch-up vaccination with the 10-valent pneumococcal non-typeable Haemophilus influenzae Protein D conjugate vaccine (PHiD-CV) in Malian children. This phase III, open-label study (NCT00985465) was conducted in Ouelessebougou, Mali, between November 2009 and July 2010. The study population consisted of PHiD-CV unprimed Malian children previously enrolled in the control group of study NCT00678301 receiving a 2-dose catch-up vaccination with PHiD-CV in the second year of life. Adverse events were recorded following each PHiD-CV dose. Antibody responses and opsonophagocytic activity (OPA) were measured pre-vaccination and after the second PHiD-CV catch-up dose. Swelling and fever (axillary temperature ≥ 37.5°C) were the most frequently reported solicited symptoms following either PHiD-CV dose. Few grade 3 solicited symptoms were reported. Large swelling reactions and serious adverse events were not reported. Post-catch-up vaccination, for each vaccine pneumococcal serotype, at least 94.7% of subjects had antibody concentrations ≥ 0.2 μg/ml, except for serotypes 6B (82.5%) and 23F (87.7%). At least 94.0% of subjects had OPA titres ≥ 8, except for serotype 19F (89.4%). The geometric mean concentration for antibodies against protein D was 839.3 (95% CI: 643.5-1094.6) EL.U/ml. Two-dose PHiD-CV catch-up regimen in the second year of life was well-tolerated and immunogenic for all vaccine pneumococcal serotypes and NTHi protein D when administered to Malian children
Collapse
Key Words
- 22F-ELISA, 22F-inhibition enzyme-linked immunosorbent assay
- 7vCRM, 7-valent pneumococcal CRM197 conjugate vaccine
- AE, adverse event
- ATP, according-to-protocol
- CI, confidence interval
- DTPw-HBV/Hib, diphtheria-tetanus-whole-cell pertussis, hepatitis B virus/Haemophilus influenzae type b vaccine
- EL.U, ELISA unit
- GAVI, Global Alliance for Vaccines and Immunization
- GMC, geometric mean concentration
- GMT, geometric mean titer
- IPD, invasive pneumococcal disease
- IgG, immunoglobulin G
- LAR, legally acceptable representative
- Mali
- NTHi, non-typeable Haemophilus influenzae
- OPA, opsonophagocytic activity
- OPV, oral live attenuated poliovirus vaccine
- PCV, pneumococcal conjugate vaccine
- PHiD-CV
- PHiD-CV, pneumococcal non-typeable Haemophilus influenzae (NTHi) protein D conjugate vaccine
- SAE, serious adverse event
- SD, standard deviation
- catch-up vaccination
- immunogenicity
- pneumococcal conjugate vaccine
- reactogenicity
- safety
Collapse
Affiliation(s)
- Alassane Dicko
- a Malaria Research and Training Center; Faculty of Medicine; Pharmacy and Dentistry; University of Bamako ; Bamako , Mali
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Iwata S, Kawamura N, Kuroki H, Tokoeda Y, Miyazu M, Iwai A, Oishi T, Sato T, Suyama A, François N, Shafi F, Ruiz-Guiñazú J, Borys D. Immunogenicity and safety of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) co-administered with DTPa vaccine in Japanese children: A randomized, controlled study. Hum Vaccin Immunother 2016; 11:826-37. [PMID: 25830489 PMCID: PMC4514407 DOI: 10.1080/21645515.2015.1012019] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
This phase III, randomized, open-label, multicenter study (NCT01027845) conducted in Japan assessed the immunogenicity, safety, and reactogenicity of 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV, given intramuscularly) co-administered with diphtheria-tetanus-acellular pertussis vaccine (DTPa, given subcutaneously). Infants (N=360 ) were randomized (2:1) to receive either PHiD-CV and DTPa (PHiD-CV group) or DTPa alone (control group) as 3-dose primary vaccination (3–4–5 months of age) and booster vaccination (17–19 months of age). Immune responses were measured before and one month after primary/booster vaccination and adverse events (AEs) were recorded. Post-primary immune responses were non-inferior to those in pivotal/efficacy European or Latin American pneumococcal protein D-conjugate vaccine studies. For each PHiD-CV serotype, at least 92.6% of infants post-primary vaccination and at least 97.7% of children post-booster had pneumococcal antibody concentrations ≥0.2 μg/ml, and at least 95.4% post-primary and at least 98.1% post-booster had opsonophagocytic activity (OPA) titers ≥8 . Geometric mean antibody concentrations and OPA titers (except OPA titer for 6B) were higher post-booster than post-priming for each serotype. All PHiD-CV-vaccinated children had anti-protein D antibody concentrations ≥100 EL.U/ml one month post-primary/booster vaccination and all were seroprotected/seropositive against each DTPa antigen. Redness and irritability were the most common solicited AEs in both groups. Incidences of unsolicited AEs were comparable between groups. Serious AEs were reported for 47 children (28 in PHiD-CV group); none were assessed as vaccine-related. In conclusion, PHiD-CV induced robust immune responses and was well tolerated when co-administered with DTPa in a 3-dose priming plus booster regimen to Japanese children.
Collapse
Key Words
- 7vCRM, 7-valent pneumococcal CRM-conjugate vaccine
- AE, adverse event
- AOM, acute otitis media
- ATP, according-to-protocol
- CAP, community-acquired pneumonia
- CI, confidence interval
- COMPAS, Clinical Otitis Media and PneumoniA Study
- DTPa, diphtheria-tetanus-acellular pertussis
- ELISA, enzyme-linked immunosorbent assay
- GMC, geometric mean concentration
- GMT, geometric mean titer
- HBV, hepatitis B virus
- Hib, Haemophilus influenzae type b
- IPD, invasive pneumococcal disease
- Japan
- NTHi, nontypeable Haemophilus influenzae
- OPA, opsonophagocytic activity
- PCV, pneumococcal conjugate vaccine
- PHiD-CV, 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine
- POET, Pneumococcal Otitis Efficacy Trial
- SAE, serious adverse event
- SAS, Statistical Analysis System
- SDD, SAS Drug and Development
- WHO, World Health Organization
- children
- co-administration
- immunogenicity
- pneumococcal conjugate vaccine
- safety
Collapse
Affiliation(s)
- Satoshi Iwata
- a Department of Infectious Diseases ; School of Medicine; Keio University ; Shinjuku-ku , Tokyo , Japan
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Ren D, Almudevar AL, Pichichero ME. Synchrony in serum antibody response to conserved proteins of Streptococcus pneumoniae in young children. Hum Vaccin Immunother 2015; 11:489-97. [PMID: 25692218 DOI: 10.4161/21645515.2014.990861] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
Conserved Streptococcus pneumoniae (Spn) proteins are currently under investigation as vaccine candidates. We recently identified a subset of children prone to frequent acute otitis media (AOM) that we refer to as stringently-defined otitis prone (sOP). We investigated the synchrony of serum antibody responses against 5 Spn protein vaccine antigens, PhtD, LytB, PcpA, PhtE, and PlyD1 resulting from nasopharyngeal colonization and AOM in sOP children (49 observations) and non-otitis prone (NOP) children (771 observations). Changes in serum IgG and IgM were quantitated with ELISA. IgG antibody concentrations against PhtD, PcpA, and PlyD1 rose in synchrony in sOP and NOP children; that is, the proteins appeared equally and highly immunogenic in children at age 6 to 15 months and then leveled off in their rise at 15 to 25 months. In contrast, rises in concentrations to PhtE and LytB were significantly slower and had not peaked in children even at 25 months of age, consistent with lower immunogenicity. Serum IgM responses against PhtD and PlyD1 were in synchrony in children at age 6-25 months old. PcpA did not induce a significant increase of serum IgM response in children, suggesting that primary responses to PcpA occurred prior to children attaining age 6 months old. PhtD, PcpA, and Ply elicit a synchronous natural acquisition of serum antibody in young children suggesting that a trivalent Spn protein vaccine combining PhtD, PcpA, and PlyD1 would be less likely to display antigen competition when administered as a combination vaccine in young children.
Collapse
Key Words
- AOM, acute otitis media
- ELISA, Enzyme-linked Immunosorbent Assay
- GAM, generalized additive model
- GAMM, generalized additive mixed model
- LC, log10 Concentration
- LME, linear mixed effects
- NOP, non-otitis prone
- NP, nasopharyngeal
- OP, otitis prone
- PCV, pneumococcal conjugate vaccine
- PcpA, pneumococcal choline binding protein A
- PhtD, pneumococcal histidine triad protein D
- PhtE, pneumococcal histidine triad protein E
- Ply, pneumolysin
- PlyD1, pneumolysin derivative 1
- Spn, Streptococcus pneumoniae
- Streptococcus pneumoniae
- generalized additive mixed model
- generalized additive model
- nasopharynx
- pneumococcal choline binding protein A
- pneumococcal conjugate vaccine
- pneumococcal histidine triad protein D
- pneumococcal histidine triad protein E
- pneumolysin
- sOP, stringently-defined otitis prone
Collapse
Affiliation(s)
- Dabin Ren
- a Rochester General Hospital Research Institute ; Rochester , NY USA
| | | | | |
Collapse
|
6
|
Lee KY, Tsai MS, Kuo KC, Tsai JC, Sun HY, Cheng AC, Chang SY, Lee CH, Hung CC. Pneumococcal vaccination among HIV-infected adult patients in the era of combination antiretroviral therapy. Hum Vaccin Immunother 2015; 10:3700-10. [PMID: 25483681 DOI: 10.4161/hv.32247] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023] Open
Abstract
HIV-infected patients remain at higher risk for pneumococcal disease than the general population despite immune reconstitution and suppression of HIV replication with combination antiretroviral therapy. Vaccination with 23-valent pneumococcal polysaccharide vaccine (PPV23) composed of T-cell-independent antigens has been recommended to reduce the risk of pneumococcal disease in HIV-infected adults. However, given the heterogeneity of study design, execution and subjects enrolled, studies examining serological responses to PPV23 yielded conflicting results and observational studies of clinical effectiveness only provided moderate evidence to support the routine use of PPV23 in HIV-infected adults. Pneumococcal conjugate vaccine (PCV), with conjugation of the capsular polysaccharide to a protein carrier, is more immunogenic than PPV23 and has been demonstrated to protect against pneumococcal disease in HIV-infected children and recurrent invasive pneumococcal disease in HIV-infected adolescents and adults. Guidelines have recently been revised to recommend that HIV-infected patients aged 19 y or older receive one dose of 13-valent pneumococcal conjugate vaccine (PCV13) followed by a booster vaccination with PPV23. In this paper, we review the studies using different vaccination strategies to improve immunogenicity among HIV-infected adult patients.
Collapse
Key Words
- ACIP, Advisory Committee on Immunization Practices
- AIDS
- ART, antiretroviral therapy
- DHHS, Department of Health and Human Services
- EACS, European AIDS Clinical Society
- ELISA, enzyme-linked immunosorbent assay
- GMT, geometric mean titer
- IPD, invasive pneumococcal disease
- NA, not available
- OPA, opsonophagocytic activity
- PCV, pneumococcal conjugate vaccine
- PCV13, 13-valent pneumococcal conjugate vaccine
- PCV7, 7-valent pneumococcal conjugate vccine
- PPV, pneumococcal polysaccharide vaccine
- PPV23, 23-valent pneumococcal polysaccharide vaccine
- PVL, plasma HIV RNA load
- Streptococcus pneumoniae
- TLR, toll-like receptor
- cART, combination antiretroviral therapy
- immunodeficiency
- immunogenicity
- invasive pneumococcal disease
- pneumococcal conjugate vaccine
- pneumococcal disease
- pneumococcal polysaccharide vaccine
Collapse
Affiliation(s)
- Kuan-Yeh Lee
- a Department of Internal Medicine ; National Taiwan University Hospital; Hsin-Chu Branch ; Hsin-Chu , Taiwan
| | | | | | | | | | | | | | | | | |
Collapse
|